دورية أكاديمية
أعرض في EDS

Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.

التفاصيل البيبلوغرافية
العنوان: Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV.
المؤلفون: Knudsen-Baas KM; Department of Clinical Medicine, University of Bergen, Post Box 7804, 5020, Bergen, Norway. Kristin.Knudsen-Baas@uib.no., Johannesen TB; Department of Registration, Cancer Registry of Norway, Ullernchausseen 64, Oslo, 0379, Norway., Myklebust TÅ; Department of Registration, Cancer Registry of Norway, Ullernchausseen 64, Oslo, 0379, Norway.; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Post Box 1600, 6026, Ålesund, Norway., Aarseth JH; Department of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway., Owe JF; Department of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway., Gilhus NE; Department of Clinical Medicine, University of Bergen, Post Box 7804, 5020, Bergen, Norway.; Department of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway., Storstein AM; Department of Neurology, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
المصدر: Journal of neuro-oncology [J Neurooncol] 2018 Dec; Vol. 140 (3), pp. 739-748. Date of Electronic Publication: 2018 Nov 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York : Springer
Original Publication: Boston : M. Nijhoff, 1983-
مواضيع طبية MeSH: Anticonvulsants/*adverse effects , Antidepressive Agents/*adverse effects , Anxiety/*chemically induced , Brain Neoplasms/*drug therapy , Depression/*chemically induced , Glioma/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/complications ; Brain Neoplasms/psychology ; Cohort Studies ; Female ; Glioma/complications ; Glioma/psychology ; Humans ; Levetiracetam/adverse effects ; Male ; Middle Aged ; Registries ; Risk Factors ; Treatment Outcome ; Young Adult
مستخلص: Introduction: Glioma is the most common intracranial primary brain tumor. Patients with glioma often suffer from epilepsy, anxiety and depression. Aims of this study were to identify risk factors for drug-treated anxiety and depression, and to determine the use of psychiatric medication in a national glioma cohort.
Methods: Data from the Cancer Registry of Norway on all persons diagnosed with glioma WHO grade II-IV 2004-2010 were linked with data from the Norwegian Prescription Database. Cox regression analysis was used to assess risk factors for drug-treated anxiety and depression. Standardized incidence ratios were calculated for psychiatric medication dispensed to glioma patients and compared to the general population.
Results: The glioma cohort consisted of 1056 males and 772 females. Of the 1828 patients, 565 had glioma grade II-III, and 1263 had grade IV. The patients with glioma grade II-III who were treated with levetiracetam had an increased risk for drug-treated anxiety compared to patients without levetiracetam; hazard ratio 2.8 (95% confidence interval 1.7-4.9). Female gender increased the risk for drug-treated anxiety compared to males in patients with glioma grade IV; hazard ratio 1.5 (95% confidence interval 1.2-2.0). Antidepressants were less frequently dispensed to patients with glioma grade II-III and epilepsy than to the general population.
Conclusions: Patients with glioma grade II-III on levetiracetam had an increased risk for drug-treated anxiety. The subgroup of patients with glioma grade II-III and epilepsy received less antidepressants than the general population.
References: Lancet Neurol. 2007 May;6(5):421-30. (PMID: 17434097)
Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
Cochrane Database Syst Rev. 2013 May 31;(5):CD006932. (PMID: 23728663)
Epilepsy Behav. 2003 Oct;4(5):515-21. (PMID: 14527494)
Epilepsy Behav. 2017 Nov;76:24-31. (PMID: 28931473)
J Neurol. 2009 Sep;256(9):1519-26. (PMID: 19434440)
Oncologist. 2014 Jul;19(7):751-9. (PMID: 24899645)
J Neurol. 2017 May;264(5):921-927. (PMID: 28315958)
Curr Neurol Neurosci Rep. 2017 Jan;17(1):5. (PMID: 28138871)
Curr Neuropharmacol. 2012 Jun;10(2):124-33. (PMID: 23204982)
Brain. 2012 Apr;135(Pt 4):1002-16. (PMID: 22171351)
Neuro Oncol. 2000 Oct;2(4):221-8. (PMID: 11265231)
Nat Rev Neurol. 2016 Apr;12(4):204-16. (PMID: 26965673)
Epilepsy Behav. 2017 May;70(Pt A):5-9. (PMID: 28407526)
Epilepsy Behav. 2013 Mar;26(3):440-9. (PMID: 23092694)
Neurology. 2000 May 23;54(10):1886-93. (PMID: 10822423)
Lancet Oncol. 2017 Jun;18(6):e315-e329. (PMID: 28483413)
Clin Neurol Neurosurg. 2017 May;156:55-62. (PMID: 28334687)
Neuro Oncol. 2008 Apr;10(2):171-81. (PMID: 18314416)
CNS Drugs. 2011 Oct 1;25(10):901-5. (PMID: 21936590)
Eur J Cancer. 2009 May;45(7):1218-31. (PMID: 19091545)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Epilepsy Behav. 2018 Feb;79:247-248. (PMID: 29274815)
Epilepsia. 2013 Dec;54 Suppl 9:12-7. (PMID: 24328866)
Epilepsia. 2017 Jul;58(7):1123-1130. (PMID: 28464309)
J Clin Oncol. 2014 Mar 10;32(8):774-82. (PMID: 24516010)
Eur J Oncol Nurs. 2017 Oct;30:113-119. (PMID: 29031307)
BMJ Open. 2018 Jan 24;8(1):e018101. (PMID: 29371271)
Seizure. 2018 Feb;55:76-82. (PMID: 29414139)
Br J Cancer. 2004 Jan 26;90(2):314-20. (PMID: 14735170)
Epilepsia. 2017 Jun;58(6):973-982. (PMID: 28470748)
Pharmacol Rev. 2013 Dec 11;66(1):80-101. (PMID: 24335193)
Lancet Oncol. 2012 Sep;13(9):e375-82. (PMID: 22935237)
J Affect Disord. 2012 Dec 10;141(2-3):343-51. (PMID: 22727334)
Arch Neurol. 1994 Feb;51(2):164-74. (PMID: 8304842)
Neuro Oncol. 2012 Apr;14(4):392-404. (PMID: 22307475)
Neuro Oncol. 2015 Apr;17(4):488-504. (PMID: 25358508)
J Neurooncol. 2017 Dec;135(3):571-579. (PMID: 28861666)
Eur J Neurol. 2017 Oct;24(10):1283-1289. (PMID: 28796376)
Eur J Neurol. 2010 Sep;17(9):1124-33. (PMID: 20718851)
J Clin Oncol. 2015 Mar 20;33(9):1023-9. (PMID: 25667287)
Epilepsy Behav. 2015 Feb;43:149-58. (PMID: 25599986)
Biol Psychiatry. 2007 Aug 15;62(4):345-54. (PMID: 17223086)
Epilepsy Behav. 2016 Aug;61:287-291. (PMID: 26926001)
Epilepsy Behav. 2003 Apr;4(2):124-32. (PMID: 12697136)
Neuro Oncol. 2013 Jul;15(7):961-7. (PMID: 23680820)
Mayo Clin Proc. 2006 Oct;81(10):1361-7. (PMID: 17036562)
Epilepsy Behav. 2008 Jul;13 Suppl 1:S1-29. (PMID: 18502183)
Int Rev Psychiatry. 2017 Oct;29(5):409-424. (PMID: 28681667)
معلومات مُعتمدة: PhD scholarship Universitetet i Bergen
فهرسة مساهمة: Keywords: Antiepileptic drugs; Anxiety; Depression; Epilepsy; Glioma
المشرفين على المادة: 0 (Anticonvulsants)
0 (Antidepressive Agents)
44YRR34555 (Levetiracetam)
تواريخ الأحداث: Date Created: 20181125 Date Completed: 20190128 Latest Revision: 20190128
رمز التحديث: 20240628
DOI: 10.1007/s11060-018-03007-9
PMID: 30471051
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7373
DOI:10.1007/s11060-018-03007-9